Schrödinger: Positive Signs Despite The Share Price Decline
- Schrödinger's growth was soft in the third quarter, and the company's losses continue to grow due to investments in internal programs.
- Operating expenses are expected to level out going forward, though, and Schrödinger should soon return to YoY growth.
- Despite short-term investor skepticism, the Novartis deal and progress by partners further validate Schrödinger's approach to drug discovery.
- While Schrödinger is deeply undervalued and has sufficient cash to continue advancing internal programs, positive clinical data will likely be needed for the stock to rise.
AnthiaCumming
While Schrödinger's (NASDAQ:SDGR) growth was soft in the third quarter, and the company's losses continue to grow, progress by partners and the recently announced Novartis deal both validate the company's approach to drug discovery. The Novartis deal is also material
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
